Genscript Biotech Co. (OTCMKTS:GNNSF) Sees Large Decrease in Short Interest

Genscript Biotech Co. (OTCMKTS:GNNSF) was the target of a large decline in short interest in June. As of June 30th, there was short interest totaling 2,832,000 shares, a decline of 42.3% from the June 15th total of 4,910,000 shares. Based on an average daily trading volume, of 5 shares, the short-interest ratio is presently 566,400.0 days.

Genscript Biotech Stock Performance

OTCMKTS:GNNSF remained flat at C$1.50 on Friday. Genscript Biotech has a one year low of C$1.30 and a one year high of C$2.42. The stock’s fifty day moving average is C$1.63 and its 200-day moving average is C$1.62.

About Genscript Biotech

GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.

The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.